Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women

被引:58
作者
van Nieuwkoop, Cees [1 ,2 ]
van der Starre, Willize E. [2 ]
Stalenhoef, Janneke E. [2 ]
van Aartrijk, Anna M. [2 ]
van der Reijden, Tanny J. K. [2 ]
Vollaard, Albert M. [2 ]
Delfos, Nathalie M. [3 ]
van 't Wout, Jan W. [2 ,4 ]
Blom, Jeanet W. [5 ]
Spelt, Ida C. [6 ]
Leyten, Eliane M. S. [7 ]
Koster, Ted [8 ]
Ablij, Hans C. [9 ]
van der Beek, Martha T. [10 ]
Knol, Mirjam J. [11 ]
van Dissel, Jaap T. [2 ,11 ]
机构
[1] Haga Teaching Hosp, Dept Internal Med, Els Borst Eilerspl 245, NL-2545 AA The Hague, Netherlands
[2] Leiden Univ, Dept Infect Dis, Med Ctr, Leiden, Netherlands
[3] Alrijne Hosp, Dept Internal Med, Leiderdorp, Netherlands
[4] Bronovo Hosp, Dept Internal Med, The Hague, Netherlands
[5] Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands
[6] Primary Hlth Care Ctr, Wassenaar, Netherlands
[7] Med Ctr Haaglanden, Dept Internal Med, The Hague, Netherlands
[8] Groene Hart Hosp, Dept Internal Med, Gouda, Netherlands
[9] Alrijne Hosp, Dept Internal Med, Leiden, Netherlands
[10] Leiden Univ, Dept Med Microbiol, Med Ctr, Leiden, Netherlands
[11] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control CIb, Bilthoven, Netherlands
关键词
Antibiotic therapy; Treatment duration; Pyelonephritis; Urinary tract infection; ESCHERICHIA-COLI STRAINS; UNCOMPLICATED CYSTITIS; ACUTE PYELONEPHRITIS; CIPROFLOXACIN; RESISTANCE;
D O I
10.1186/s12916-017-0835-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In adults with febrile urinary tract infection (fUTI), data on optimal treatment duration in patients other than non-pregnant women without comorbidities are lacking. Methods: A randomized placebo-controlled, double-blind, non-inferiority trial among 35 primary care centers and 7 emergency departments of regional hospitals in the Netherlands. Women and men aged >= 18 years with a diagnosis of fUTI were randomly assigned to receive antibiotic treatment for 7 or 14 days (the second week being ciprofloxacin 500 mg or placebo orally twice daily). Patients indicated to receive antimicrobial treatment for at least 14 days were excluded from randomization. The primary endpoint was the clinical cure rate through the 10-to 18-day post-treatment visit with preset subgroup analysis including sex. Secondary endpoints were bacteriologic cure rate at 10-18 days post-treatment and clinical cure at 70-84 days post-treatment. Results: Of 357 patients included, 200 were eligible for randomization; 97 patients were randomly assigned to 7 days and 103 patients to 14 days of treatment. Overall, short-term clinical cure occurred in 85 (90%) patients treated for 7 days and in 94 (95%) of those treated for 14 days (difference -4.5%; 90% CI, -10.7 to 1.7; Pnon-inferiority = 0. 072, non-inferiority not confirmed). In women, clinical cure was 94% and 93% in those treated for 7 and 14 days, respectively (difference 0.9; 90% CI, -6.9 to 8.7, Pnon-inferiority = 0.011, non-inferiority confirmed) and, in men, this was 86% versus 98% (difference -11.2; 90% CI -20.6 to -1.8, P-superiority = 0.025, inferiority confirmed). The bacteriologic cure rate was 93% versus 97% (difference -4.3%; 90% CI, -9.7 to 1.2, Pnon-inferiority = 0.041) and the long-term clinical cure rate was 92% versus 91% (difference 1.6%; 90% CI, -5.3 to 8.4; Pnon-inferiority = 0.005) for 7 days versus 14 days of treatment, respectively. In the subgroups of men and women, long-term clinical cure rates met the criteria for non-inferiority, indicating there was no difference in the need for antibiotic retreatment for UTI during 70-84 days follow-up post-treatment. Conclusions: Women with fUTI can be treated successfully with antibiotics for 7 days. In men, 7 days of antibiotic treatment for fUTI is inferior to 14 days during short-term follow-up but it is non-inferior when looking at longer follow-up.
引用
收藏
页数:9
相关论文
共 23 条
[1]   Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey [J].
Arslan, H ;
Azap, ÖK ;
Ergönül, Ö ;
Timurkaynak, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (05) :914-918
[2]   ANATOMICAL BARRIERS FOR ANTIMICROBIAL AGENTS [J].
BARZA, M .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1993, 12 :31-35
[3]   Quinolone resistance among Escherichia coli strains from community-acquired urinary tract infections in Greece [J].
Chaniotaki, S ;
Giakouppi, P ;
Tzouvelekis, LS ;
Panagiotakos, D ;
Kozanitou, M ;
Petrikkos, G ;
Avlami, A ;
Vatopoulos, AC .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (01) :75-78
[4]   Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics [J].
D'Agostino, RB ;
Massaro, JM ;
Sullivan, LM .
STATISTICS IN MEDICINE, 2003, 22 (02) :169-186
[5]   Urinary Tract Infection in Male Veterans Treatment Patterns and Outcomes [J].
Drekonja, Dimitri M. ;
Rector, Thomas S. ;
Cutting, Andrea ;
Johnson, James R. .
JAMA INTERNAL MEDICINE, 2013, 173 (01) :62-68
[6]   Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials [J].
Eliakim-Raz, Noa ;
Yahav, Dafna ;
Paul, Mical ;
Leibovici, Leonard .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (10) :2183-2191
[7]   Diagnosis and Management of Urinary Tract Infections in the Outpatient Setting A Review [J].
Grigoryan, Larissa ;
Trautner, Barbara W. ;
Gupta, Kalpana .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (16) :1677-1684
[8]  
Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]
[9]   Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women - A randomized trial [J].
Hooton, TM ;
Scholes, D ;
Gupta, K ;
Stapleton, AE ;
Roberts, PL ;
Stamm, WE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (08) :949-955
[10]   A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis [J].
Klausner, Howard A. ;
Brown, Patricia ;
Peterson, Janet ;
Kaul, Simrati ;
Khashab, Mohammed ;
Fisher, Alan C. ;
Kahn, James B. .
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (11) :2637-2645